posted on 2020-08-26, 20:11authored byMehmet Senel, Esma Dervisevic, Sammy Alhassen, Muamer Dervisevic, Amal Alachkar, Victor J. Cadarso, Nicolas H. Voelcker
Parkinson’s
disease (PD) is a progressive neurodegenerative
disorder involving dopaminergic neurons from the substantia nigra.
The loss of dopaminergic neurons results in decreased dopamine (DA)
release in the striatum and thus impaired motor functions. DA is one
of the key neurotransmitters monitored for the diagnosis and during
the progression and treatment of PD. Therefore, sensitive and selective
DA detection methods are of high clinical relevance. In this study,
a new microfluidic device utilized for electrochemical DA detection
is reported. The microfluidic sensing device operates in the range
of 0.1–1000 nM DA requiring only ∼2.4 μL sample
volume, which corresponds to detectable 240 amol of DA. Using this
sensor, we were able to monitor the changes in DA levels in cerebrospinal
fluid and plasma of a mouse model of PD and following the treatment
of drug l-3,4-dihydroxyphenylalanine.